Latest Period
Q2 2026
Security Snapshot
DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) Institutional Ownership
CUSIP: 25253X207
13F Institutional Holders and Ownership History from Q4 2018 to Q2 2026
Institutions Reporting
88
Shares (Excl. Options)
12,472,522
Price
$7.04
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Voting Common Shares, no par value
- Symbol
- DMAC on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 12,472,522
- Total 13F value
- $87,805,815
- Portfolio coverage rank
- 0%
- Share change
- +1,654,250
- Value change
- +$11,900,272
- Number of holders
- 88
- Shares outstanding
- 52,272,727
- SEC-reported price per share
- $6.51
- Insider filing price
- $6.51
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value is tracked under CUSIP 25253X207.
- 88 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 99 to 88 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $79,166,917 to $87,805,815.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 88 institutions filings for Q2 2026.
Security key
25253X207
Latest holder period
Q2 2026
13F holders
88
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
DMAC full holder history
DiaMedica Therapeutics Inc. SEC filings
DiaMedica Therapeutics Inc. company facts
DiaMedica Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 25253X207:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
DMAC
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| TRILL AB | 17% | +13% | $70,252,906 | +$8,447,765 | 8,825,742 | +14% | TRILL AB | 31 Dec 2025 |
| TomEnterprise AB | 16% | $32,695,950 | 8,383,577 | TomEnterprise AB | 23 Jul 2025 | |||
| JACINTO RICHARD II | 9.6% | $34,067,114 | 4,958,823 | Richard Jacinto II | 30 Sep 2025 | |||
| COOPERMAN LEON G | 6.6% | +5% | $28,462,500 | +$1,486,972 | 3,450,000 | +5.5% | Cooperman Leon G. | 31 Dec 2025 |
As of 30 Jun 2026, 88 institutional investors reported holding 12,472,522 shares of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC). This represents 24% of the company’s total 52,272,727 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
22%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| COOPERMAN LEON G | 6.6% | 3,450,000 | +71% | 0.68% | $24,288,000 |
| BlackRock, Inc. | 4.3% | 2,252,285 | +21% | 0% | $15,856,086 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 894,115 | +15% | 0% | $6,296,035 |
| MILLENNIUM MANAGEMENT LLC | 1.6% | 845,309 | -9.6% | 0% | $5,950,975 |
| STATE STREET CORP | 1.2% | 646,743 | +0.39% | 0% | $4,553,071 |
| Bleichroeder LP | 0.73% | 382,317 | 0% | 0.48% | $2,691,512 |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.68% | 355,523 | +6.6% | 0% | $2,502,882 |
| OSAIC HOLDINGS, INC. | 0.65% | 338,107 | +5.8% | 0% | $2,380,261 |
| NORTHERN TRUST CORP | 0.63% | 327,518 | -3.3% | 0% | $2,305,727 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.48% | 251,671 | +24% | 0% | $1,771,764 |
| LPL Financial LLC | 0.45% | 233,500 | +3.3% | 0% | $1,643,840 |
| VANGUARD FIDUCIARY TRUST CO | 0.4% | 207,438 | +11% | 0% | $1,460,364 |
| GOLDMAN SACHS GROUP INC | 0.32% | 168,066 | +183% | 0% | $1,183,185 |
| CITADEL ADVISORS LLC | 0.28% | 145,870 | +0.1% | 0% | $1,026,925 |
| Squarepoint Ops LLC | 0.28% | 145,247 | 0% | $1,022,539 | |
| Bank of New York Mellon Corp | 0.23% | 117,820 | +6.1% | 0% | $829,449 |
| MEMBERS WEALTH LLC | 0.19% | 101,382 | 0% | 0.39% | $713,729 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.18% | 96,691 | +9.4% | 0% | $680,705 |
| COBALT CAPITAL MANAGEMENT, INC. | 0.17% | 90,000 | 0.45% | $633,600 | |
| Trexquant Investment LP | 0.16% | 84,648 | +280% | 0% | $595,922 |
| MAGNOLIA CAPITAL ADVISORS LLC | 0.15% | 77,405 | 0% | 0.09% | $544,931 |
| Diametric Capital, LP | 0.15% | 76,621 | 0.06% | $539,411 | |
| GSA CAPITAL PARTNERS LLP | 0.14% | 72,565 | +24% | 0.03% | $511,000 |
| Blue Trust, Inc. | 0.13% | 69,122 | 0% | 0.01% | $486,619 |
| BANK OF AMERICA CORP /DE/ | 0.11% | 57,712 | +35% | 0% | $406,292 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
31
Latest
Q2 2026
Rows shown
1-25 of 31
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 12,472,522 | $87,805,815 | +$11,900,272 | $7.04 | 88 |
| 2026 Q1 | 11,698,808 | $79,166,917 | -$2,896,262 | $6.77 | 99 |
| 2025 Q4 | 12,053,996 | $95,986,433 | -$5,768,433 | $7.96 | 92 |
| 2025 Q3 | 12,754,591 | $82,807,935 | +$25,371,563 | $6.87 | 77 |
| 2025 Q2 | 8,764,697 | $34,183,334 | +$4,951,594 | $3.90 | 58 |
| 2025 Q1 | 7,514,092 | $28,477,666 | +$2,854,596 | $3.79 | 57 |
| 2024 Q4 | 6,729,012 | $36,539,618 | +$6,248,431 | $5.43 | 45 |
| 2024 Q3 | 5,580,411 | $23,326,555 | +$2,250,136 | $4.19 | 40 |
| 2024 Q2 | 5,062,392 | $14,934,296 | +$1,369,212 | $2.95 | 32 |
| 2024 Q1 | 4,598,019 | $12,730,274 | +$2,073,072 | $2.77 | 31 |
| 2023 Q4 | 3,840,738 | $10,907,609 | -$629,214 | $2.84 | 37 |
| 2023 Q3 | 4,250,465 | $10,966,479 | +$1,920,978 | $2.58 | 35 |
| 2023 Q2 | 3,490,534 | $15,080,277 | +$4,150,477 | $4.32 | 30 |
| 2023 Q1 | 2,565,385 | $3,924,875 | +$61,558 | $1.53 | 22 |
| 2022 Q4 | 2,524,139 | $3,989,530 | -$6,541 | $1.58 | 27 |
| 2022 Q3 | 2,527,104 | $3,132,035 | -$2,355,232 | $1.24 | 23 |
| 2022 Q2 | 3,668,922 | $7,411,731 | -$802,498 | $2.02 | 24 |
| 2022 Q1 | 4,006,054 | $10,017,522 | -$427,839 | $2.50 | 28 |
| 2021 Q4 | 3,993,298 | $14,891,858 | +$4,430,787 | $3.73 | 34 |
| 2021 Q3 | 2,804,345 | $11,247,922 | -$4,241,878 | $4.01 | 31 |
| 2021 Q2 | 3,783,974 | $16,902,446 | -$48,644,584 | $4.45 | 38 |
| 2021 Q1 | 5,694,347 | $88,119,211 | +$33,217,401 | $9.15 | 38 |
| 2020 Q4 | 5,983,974 | $60,607,941 | +$30,865 | $10.14 | 34 |
| 2020 Q3 | 6,707,026 | $28,383,192 | +$15,491,837 | $4.24 | 30 |
| 2020 Q2 | 3,034,327 | $21,027,519 | +$1,227,002 | $6.93 | 20 |